Qinling Jiang - Publications

Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States.

Journal: Frontiers in public health

Published: January 10, 2026

Cost-effectiveness of socazolimab plus chemotherapy vs. standard chemotherapy for first-line treatment of extensive-stage small cell lung cancer: a U.S. and China perspective.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 02, 2025

Exploring resistance to initial chemotherapy in small cell lung cancer: The role of bone metastasis and other clinicopathologic characteristics.

Journal: Medicine

Published: March 24, 2025

Global trends and research hotspots in perioperative management of lung cancer: a bibliometric analysis from 2004 to 2024.

Journal: Frontiers in immunology

Published: September 23, 2024

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China.

Journal: Frontiers in pharmacology

Published: July 08, 2024

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.

Journal: International journal of clinical pharmacy

Published: May 20, 2024

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system.

Journal: Frontiers in pharmacology

Published: March 19, 2024

Prognostic implications of synaptophysin, CD56, thyroid transcription factor-1, and Ki-67 in pulmonary high-grade neuroendocrine carcinomas.

Journal: Annals of diagnostic pathology

Published: October 06, 2023

Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma.

Journal: International journal of clinical pharmacy

Published: August 14, 2023

Clinical observation of Pemetrexed first-line treatment in advanced non-squamous lung cancer or non-small cell lung cancer without driver-mutations: a phase 2, single-arm trial.

Journal: Annals of translational medicine

Published: November 19, 2020